Methods of preparation of zingerone, compositions comprising zingerone, and uses therefor
Patent Information
- Application Number
- HK62026125186
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-15
- Filing Date
- 2026-06-23
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
A method for preparing gingerone from ginger, compositions obtained using these methods, and methods for using these compositions are disclosed. Specifically, beneficial compositions and methods for using them are disclosed. Abstract
Claims
CLAIMS1 A method of producing zingerone, comprising:(i) subjecting ginger root to an alkaline treatment in an alkaline solution; or(ii) subjecting juice and / or marc obtained from ginger root to an alkaline treatment in an alkaline solution; thereby producing zingerone.2 The method as claimed in claim 1 wherein the ginger root is fresh.3 The method as claimed in claim 1 or claim 2, wherein:(a) the ginger root of (i) is chopped;(b) the ginger root of (i) is chopped and dried; or(c) the juice and / or marc of (ii) is obtained via macerating and / or pressing ginger root.4 The method as claimed in any one of claims 1 to 3, wherein:(a) potassium hydroxide (KOH) is used in the alkaline solution; or(b) a liquid form of potassium hydroxide (KOH) is used in the alkaline solution.5 The method as claimed in claim 4, wherein the alkaline solution comprises:(a) about 1% to about 6% KOH (v / v);(b) about 1.5% to about 5.5% KOH (v / v);(c) about 2% to about 4% KOH (v / v);(d) about 1.5% to about 3.5% KOH (v / v); or(e) about 2% KOH (v / v).6 The method as claimed in any one of claims 1 to 3, wherein calcium hydroxide (Ca(0H)2) is used in the alkaline solution.7 The method as claimed in claim 6, wherein the alkaline solution comprises:(a) about 0.5% to about 4% Ca(OH)2 (v / v);(b) about 1.5% to about 3.5% Ca(OH)2 (v / v); or(b) about 2.0% to about 3.0% Ca(OH)2 (v / v).8 The method as claimed in any one of claims 1 to 7, wherein:(a) the alkaline treatment is carried out at about 40 to about 70 degrees Celsius;(b) the alkaline treatment is carried out at about 50 to about 60 degrees Celsius;(c) the alkaline treatment is carried out at about 55 to about 65 degrees Celsius; or(d) the alkaline treatment is carried out at about 60 degrees Celsius. The method as claimed in any one of claims 1 to 8, wherein:(a) the alkaline treatment is carried out for about 1-30 hours, about 1-20 hours, about 1-10 hours, or about 1-5 hours;(b) the alkaline treatment is carried out for about 0.5 to about 3 hours, or about 0.75 to about 2.5 hours, or about 1 to about 2 hours; or(c) the alkaline treatment is carried out for about 1 hour, or about 2 hours. The method as claimed in any one of claims 1 to 9, including a further step of:(a) neutralising the alkaline solution;(b) neutralising the alkaline solution and then drying; or(c) neutralising the alkaline solution, optionally drying, and then carrying out one or more additional extraction steps. The method as claimed in claim 10, wherein the one or more additional extraction steps include:(a) one or more ethanol extraction steps;(b) supercritical fluid extraction; or(c) a supercritical fluid extraction followed by one or more ethanol extraction step. The method as claimed in any one of claims 1 to 11, wherein the method produces a composition comprising zingerone. The method as claimed in any one of claims 1 to 12, wherein the method produces a composition that is free from aldehydes or substantially free from aldehydes. A composition comprising zingerone, wherein the zingerone is obtained by the method of any one of claims 1 to 13. The composition as claimed in claim 14, wherein the composition is formulated as a pharmaceutical composition or a dietary supplement.The composition as claimed in claim 14 or claim 15, wherein the composition is formulated as a liquid, a solid, or a semi-solid. The composition as claimed in any one of claims 14 to 16, which is formulated for topical administration or oral administration. The composition as claimed in any one of claims 14 to 17, which is formulated as a solution, tincture, gel, jelly, gummy, powder, tablet, or capsule. The composition as claimed in any one of claims 14 to 18, which is formulated to include:(a) a dose of between about 10 mg to about 1500 mg of zingerone;(b) a dose of between about 10 mg to about 1000 mg of zingerone;(c) a dose of between about 10 mg to about 150 mg of zingerone;(d) a dose of about 10 mg to about 100 mg of zingerone; or(e) a dose of about 10 mg to about 50 mg of zingerone. The composition as claimed in any one of claims 14 to 19, which is:(a) formulated for co-administration with a further anti-inflammatory agent;(b) formulated for co-administration with one or more of: an analgesic compound, antipyretic compound, and psychotropic compound;(c) formulated for co-administration with one or more of: a cannabinoid compound, mushroom compound, non-steroid anti-inflammatory drug compound (NSAID), opioid compound, salicylate compound, and steroid compound;(d) comprising one or more of: acetaminophen, aspirin, celecoxib, diclofenac, diflunisal, etodolac, etoricoxib, felbinac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, lidocaine, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tenoxicam, butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, eptazocinem, betamethasone, cortisone, deflazacort, dexamethasone, ethamethasoneb, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, cannabidiol, cannabigerol, tetrahydrocannabinol, psilocybin, and psilocin. The composition as claimed in any one of claims 14 to 20 for use in treating or preventing inflammation.The composition as claimed in claim 21, wherein the inflammation is acute or chronic inflammation. The composition as claimed in claim 22, wherein:(a) the inflammation is an inflammatory disorder;(b) the inflammation requires modulation;(c) the inflammation is associated with an immune disorder;(d) the inflammation is associated with an arthritic disorder;(e) the inflammation is associated with an infection;(f) the inflammation is associated with a cardiac, circulatory, or pulmonary disorder;(g) the inflammation is associated with a neurological disorder; and / or(h) the inflammation is associated with a neoplastic disorder. The composition as claimed in any one of claims 21 to 23, wherein the inflammation is of one or more of: a joint, skin, eye, ear, nose, mouth, throat, oesophagus, kidney, bladder, liver, spleen, lung, heart, brain, circulatory system, digestive system, endocrine system, genitourinary system, lymphatic system, nervous system, and skeletal system. The composition as claimed in any one of claims 21 to 24, wherein the inflammation is associated with one or more of: Alzheimer’s disease, early stage Alzheimer’s disease, ankylosing spondylitis, arthritis, asthma, colitis, Crohn's disease, dementia, early stage dementia, depression, diabetes, fibromyalgia, gout, infection, immune mediated inflammatory disease, inflammatory bowel disease, interstitial cystitis, multiple sclerosis, polymyalgia psoriasis, scleroderma, and Sjogren’s syndrome, and systemic lupus erythematosus. The composition as claimed in any one of claims 21 to 24, wherein the inflammation is associated with one or more of: rheumatoid arthritis, ankylosing spondylitis arthritis, fibromyalgia arthritis, gout arthritis, juvenile idiopathic arthritis (JIA), lupus arthritis, osteoarthritis, polymyalgia rheumatica, psoriatic arthritis, reactive arthritis, scleroderma arthritis, and Sjogren’s syndrome arthritis. The composition as claimed in any one of claims 21 to 24, wherein the inflammation is associated with one or more of: atherosclerosis, coronary artery disease, pulmonary artery hypertension, hypoxia-induced pulmonary hypertension,pneumonia, acute respiratory distress syndrome, coronavirus respiratory disorder, and cytokine storm syndrome; or from one or more of: breast cancer, leukaemia, multiple myeloma, myelodysplastic syndrome, pancreatic cancer, and prostate cancer. The composition as claimed in any one of claims 21 to 24, wherein the inflammation is associated with one or more of: a blister, dermatitis, eczema, hive, lesion, papule, plaque, psoriasis, rash, rosacea, ulcer, and wound. Use of a composition as claimed in claim 14 for preparing a medicament for treating or preventing inflammation in a subject. The use as claimed in claim 29, wherein the medicament provides for reducing or slowing progression of the inflammation. The use as claimed in claim 29 or claim 30, wherein:(a) the medicament is formulated as a solid, semi-solid, or liquid; and / or(b) the medicament is formulated for topical administration or oral administration. The use as claimed in any one of claims 29 to 31, wherein the medicament is formulated as a solution, gel, jelly, gummy, powder, tablet, or capsule. The use as claimed in claim 32, wherein the medicament is formulated to include:(a) a dose of between about 10 mg to about 1500 mg of zingerone;(b) a dose of between about 10 mg to about 1000 mg of zingerone;(c) a dose of between about 10 mg to about 150 mg of zingerone;(d) a dose of about 10 mg to about 100 mg of zingerone; or(e) a dose of about 10 mg to about 50 mg of zingerone. The use as claimed in any one of claims 29 to 33, wherein:(a) the composition is formulated for co-administration with a further antiinflammatory agent;(b) the composition is formulated for co-administration with one or more of: an analgesic compound, antipyretic compound, and psychotropic compound;(c) the composition is formulated for co-administration with one or more of: a cannabinoid compound, mushroom compound, non-steroid anti-inflammatory drugcompound (NSAID), opioid compound, salicylate compound, and steroid compound;(d) the medicament comprises one or more of: acetaminophen, aspirin, celecoxib, diclofenac, diflunisal, etodolac, etoricoxib, felbinac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, lidocaine, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tenoxicam, butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, eptazocinem, betamethasone, cortisone, deflazacort, dexamethasone, ethamethasoneb, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, cannabidiol, cannabigerol, tetrahydrocannabinol, psilocybin, and psilocin. The use as claimed in any one of claims 29 to 34, wherein the inflammation is acute or chronic inflammation. The use as claimed in claim 35, wherein:(a) the inflammation is an inflammatory disorder;(b) the inflammation requires modulation;(c) the inflammation is associated with an immune disorder;(d) the inflammation is associated with an arthritic disorder;(e) the inflammation is associated with an infection;(f) the inflammation is associated with a cardiac, circulatory, or pulmonary disorder;(g) the inflammation is associated with a neurological disorder; and / or(h) the inflammation is associated with a neoplastic disorder. The use as claimed in claim 35 or claim 36, wherein the inflammation is inflammation of one or more of: a joint, skin, eye, ear, nose, mouth, throat, oesophagus, kidney, bladder, liver, spleen, lung, heart, brain, circulatory system, digestive system, endocrine system, genitourinary system, lymphatic system, nervous system, and skeletal system. The use as claimed in any one of claims 35 to 37, wherein the inflammation is associated with one or more of: Alzheimer’s disease, early stage Alzheimer’s disease, ankylosing spondylitis, arthritis, asthma, colitis, Crohn's disease, dementia, early stage dementia, depression, diabetes, fibromyalgia, gout, infection, immune mediated inflammatory disease, inflammatory bowel disease, interstitial cystitis,multiple sclerosis, polymyalgia psoriasis, scleroderma, and Sjogren’s syndrome, and systemic lupus erythematosus. The use as claimed in any one of claims 35 to 37, wherein the inflammation is associated with one or more of: rheumatoid arthritis, ankylosing spondylitis arthritis, fibromyalgia arthritis, gout arthritis, juvenile idiopathic arthritis (JIA), lupus arthritis, osteoarthritis, polymyalgia rheumatica, psoriatic arthritis, reactive arthritis, scleroderma arthritis, and Sjogren’s syndrome arthritis. The use as claimed in any one of claims 35 to 37, wherein the inflammation is associated with one or more of: atherosclerosis, coronary artery disease, pulmonary artery hypertension, hypoxia-induced pulmonary hypertension, pneumonia, acute respiratory distress syndrome, coronavirus respiratory disorder, and cytokine storm syndrome; or from one or more of: breast cancer, leukaemia, multiple myeloma, myelodysplastic syndrome, pancreatic cancer, and prostate cancer. The use as claimed in any one of claims 35 to 37, wherein the inflammation is associated with one or more of: a blister, dermatitis, eczema, hive, lesion, papule, plaque, psoriasis, rash, rosacea, ulcer, and wound. A method of treating or preventing inflammation, the method comprising administering to a subject a composition as claimed in claim 15, thereby treating or preventing the inflammation. The method as claimed in claim 42, wherein the administration reduces or slows progression the inflammation. The method as claimed in claim 42 or claim 43, wherein:(a) the composition is administered as a solid, semi-solid, or liquid; and / or(b) the composition is administered by topical administration or oral administration. The method as claimed in any one of claims 42 to 44, wherein the composition is administered as a solution, gel, jelly, gummy, powder, tablet, or capsule. The method as claimed in claim 45, wherein the composition is administered at:(a) a dose of between about 1 mg to about 5000 mg of zingerone;(b) a dose of between about 1 mg to about 1500 mg of zingerone;(c) a dose of between about 5 mg to about 500 mg of zingerone;(d) a dose of about 1 mg to about 15 mg of zingerone; or(e) a dose of about 1 mg to about 10 mg of zingerone. The method as claimed in any one of claims 42 to 46, wherein:(a) the composition is co-administered with a further anti-inflammatory agent;(b) the composition is co-administered with one or more of: an analgesic compound, antipyretic compound, and psychotropic compound;(c) the composition is co-administered with one or more of: a cannabinoid compound, mushroom compound, non-steroid anti-inflammatory drug compound (NSAID), opioid compound, salicylate compound, and steroid compound;(d) the composition is co-administered with one or more of: acetaminophen, aspirin, celecoxib, diclofenac, diflunisal, etodolac, etoricoxib, felbinac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, lidocaine, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tenoxicam, butorphanol, nalbuphine, levorphanol, levallorphan, pentazocine, phenazocine, eptazocinem, betamethasone, cortisone, deflazacort, dexamethasone, ethamethasoneb, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, cannabidiol, cannabigerol, tetrahydrocannabinol, psilocybin, and psilocin. The method as claimed in any one of claims 42 to 47, wherein the inflammation is acute or chronic inflammation. The method as claimed in claim 48, wherein:(a) the inflammation is an inflammatory disorder;(b) the inflammation requires modulation;(c) the inflammation is associated with an immune disorder;(d) the inflammation is associated with an arthritic disorder;(e) the inflammation is associated with an infection;(f) the inflammation is associated with a cardiac, circulatory, or pulmonary disorder;(g) the inflammation is associated with a neurological disorder; and / or(h) the inflammation is associated with a neoplastic disorder. The method as claimed in claim 48 or claim 49, wherein the inflammation is inflammation of one or more of: a joint, skin, eye, ear, nose, mouth, throat,oesophagus, kidney, bladder, liver, spleen, lung, heart, brain, circulatory system, digestive system, endocrine system, genitourinary system, lymphatic system, nervous system, and skeletal system. The method as claimed in any one of claims 48 to 50, wherein the inflammation is associated with one or more of: Alzheimer’s disease, early stage Alzheimer’s disease, ankylosing spondylitis, arthritis, asthma, colitis, Crohn's disease, dementia, early stage dementia, depression, diabetes, fibromyalgia, gout, infection, immune mediated inflammatory disease, inflammatory bowel disease, interstitial cystitis, multiple sclerosis, polymyalgia psoriasis, scleroderma, and Sjogren’s syndrome, and systemic lupus erythematosus. The method as claimed in any one of claims 48 to 50, wherein the inflammation is associated with one or more of: rheumatoid arthritis, ankylosing spondylitis arthritis, fibromyalgia arthritis, gout arthritis, juvenile idiopathic arthritis (JIA), lupus arthritis, osteoarthritis, polymyalgia rheumatica, psoriatic arthritis, reactive arthritis, scleroderma arthritis, and Sjogren’s syndrome arthritis. The method as claimed in any one of claims 48 to 50, wherein the inflammation is associated with one or more of: atherosclerosis, coronary artery disease, pulmonary artery hypertension, hypoxia-induced pulmonary hypertension, pneumonia, acute respiratory distress syndrome, coronavirus respiratory disorder, and cytokine storm syndrome; or from one or more of: breast cancer, leukaemia, multiple myeloma, myelodysplastic syndrome, pancreatic cancer, and prostate cancer. The method as claimed in any one of claims 48 to 50, wherein the inflammation is associated with one or more of: a blister, dermatitis, eczema, hive, lesion, papule, plaque, psoriasis, rash, rosacea, ulcer, and wound.
